Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.
Ontology highlight
ABSTRACT: Sifuvirtide (SFT) is an electrostatically constrained α-helical peptide fusion inhibitor showing potent anti-HIV activity, good safety, and pharmacokinetic profiles, and it is currently under phase II clinical trials in China. In this study, we demonstrate its potent and broad anti-HIV activity by using diverse HIV-1 subtypes and variants, including subtypes A, B, and C that dominate the AIDS epidemic worldwide, and subtypes B', CRF07_BC, and CRF01_AE recombinants that are currently circulating in China, and those possessing cross-resistance to the first and second generation fusion inhibitors. To elucidate its mechanism of action, we determined the crystal structure of SFT in complex with its target N-terminal heptad repeat region (NHR) peptide (N36), which fully supports our rational inh
SUBMITTER: Yao X
PROVIDER: S-EPMC3307288 | biostudies-literature | 2012 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA